<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1186</ReferenceId>
        <DateLastUpdated>2020-09-30-07:00</DateLastUpdated>
        <Article>
            <PubmedId>10698744</PubmedId>
            <Abstract>To determine the ability of antibodies to provide protection from Ebola viruses, monoclonal antibodies (mAbs) to the Ebola glycoprotein were generated and evaluated for efficacy. We identified several protective mAbs directed toward five unique epitopes on Ebola glycoprotein. One of the epitopes is conserved among all Ebola viruses that are known to be pathogenic for humans. Some protective mAbs were also effective therapeutically when administered to mice 2 days after exposure to lethal Ebola virus. The identification of protective mAbs has important implications for developing vaccines and therapies for Ebola virus.</Abstract>
            <ArticleYear>2000</ArticleYear>
            <ArticlePages>1664-6</ArticlePages>
            <ArticleTitle>Epitopes involved in antibody-mediated protection from Ebola virus.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Wilson</LastName>
                    <ForeName>J A</ForeName>
                </Author>
                <Author>
                    <LastName>Hevey</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Bakken</LastName>
                    <ForeName>R</ForeName>
                </Author>
                <Author>
                    <LastName>Guest</LastName>
                    <ForeName>S</ForeName>
                </Author>
                <Author>
                    <LastName>Bray</LastName>
                    <ForeName>M</ForeName>
                </Author>
                <Author>
                    <LastName>Schmaljohn</LastName>
                    <ForeName>A L</ForeName>
                </Author>
                <Author>
                    <LastName>Hart</LastName>
                    <ForeName>M K</ForeName>
                </Author>
            </Authors>
            <Affiliations>Virology Division, U.S. Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Fort Detrick, Frederick, MD 21702-5011, USA.</Affiliations>
            <ArticleChemicalList>Antibodies, Monoclonal;Antibodies, Viral;Antigens, Viral;Epitopes;Immunoglobulin G;Viral Envelope Proteins;envelope glycoprotein, Ebola virus;Complement System Proteins</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antibodies, Monoclonal(immunology); Antibodies, Viral(immunology); Antibody Affinity; Antigens, Viral(immunology); Binding, Competitive; Complement System Proteins(immunology); Ebolavirus(immunology; physiology); Epitopes(immunology); Female; Hemorrhagic Fever, Ebola(prevention &amp; control; therapy); Humans; Immunoglobulin G(immunology); Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neutralization Tests; Specific Pathogen-Free Organisms; Viral Envelope Proteins(immunology); Viral Plaque Assay</ArticleMeshHeadingsList>
            <Journal>
                <Volume>287</Volume>
                <Issue>5458</Issue>
                <Title>Science</Title>
                <Issn>1095-9203</Issn>
                <MedlineTa>Science</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>mAb 13F6 (GP 401-417)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>ATQVEQHHRRTDNDSTA</LinearSequence>
                        <StartingPosition>401</StartingPosition>
                        <EndingPosition>417</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAG40168.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>186538</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>233152</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The authors provided accession U23187 (GI 1041204) as the source of the epitope. However, this GI was not available, therefore a representative source was used.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 1665</LocationOfData>
                        <BCellId>16762</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb was tested for its ability to inhibit plaque formation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>13F6-1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367936</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976, but not Ebolavirus Sudan or Ivory Coast virus by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>13F6-1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>2367937</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976 or VEE replicons expressing GP by immunoprecipitation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>13F6-1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367938</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was identified following reactivity of overlapping 13-mer peptides. The consensus sequence was shown to be EQHHRRTDN.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>13F6-1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>ATQVEQHHRRTDNDSTA</LinearSequence>
                                        <StartingPosition>401</StartingPosition>
                                        <EndingPosition>417</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAG40168.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>2367939</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Purified Immunoglobulin</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>13F6 1-2</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG2a</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Recipient mice received i.p. injections of 100, 50 or 25ug of the mAb 1 day before or 1 and 2 days following live challenge with 300 times the lethal does.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>The epitope-specific mAb was shown to protect BALB/c (10/10) and C57BL/6 mice (9/10) from lethal challenge delivered prophylactically or therapeutically.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>mAb 6D8 (GP 389-405)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>HNTPVYKLDISEATQVE</LinearSequence>
                        <StartingPosition>389</StartingPosition>
                        <EndingPosition>405</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAG40168.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>186538</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>233197</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The authors provided accession U23187 (GI 1041204) as the source of the epitope. However, this GI was not available, therefore a representative source was used.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>2367944</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Purified Immunoglobulin</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>6D8 1-2</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG2a</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Recipient mice received i.p. injections of 100, 50 or 25ug of the mAb 1 day before or 1 and 2 days following live challenge with 300 times the lethal does.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>10</NumberOfSubjectsResponded>
                            <ResponseFrequency>100</ResponseFrequency>
                            <AssayComments>The epitope-specific mAb was shown to protect BALB/c (10/10) and C57BL/6 mice (9/10) from lethal challenge delivered prophylactically or therapeutically.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>2367942</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976 or VEE replicons expressing GP by immunoprecipitation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>6D8 1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367941</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976, but not Ebolavirus Sudan or Ivory Coast virus by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>6D8 1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367943</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was identified following reactivity of overlapping 13-mer peptides. The consensus sequence was shown to be VYKLDISEA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>6D8 1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>HNTPVYKLDISEATQVE</LinearSequence>
                                        <StartingPosition>389</StartingPosition>
                                        <EndingPosition>405</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAG40168.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 1665</LocationOfData>
                        <BCellId>2367940</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb was tested for its ability to inhibit plaque formation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>6D8 1-2</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG2a</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>mAb 12B5 (GP 477-493)</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>GKLGLITNTIAGVAGLI</LinearSequence>
                        <StartingPosition>477</StartingPosition>
                        <EndingPosition>493</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>AAG40168.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>186538</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Table 2</LocationOfData>
                <EpitopeId>162327</EpitopeId>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Epitope containing region/antigenic site</EpitopeStructureDefines>
                <EpitopeComments>The authors provided accession U23187 (GI 1041204) as the source of the epitope. However, this GI was not available, therefore a representative source was used.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <BCellId>2367947</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>39</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976 or VEE replicons expressing GP by immunoprecipitation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>12B5 1-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367948</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>37</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope was identified following reactivity of overlapping 13-mer peptides. The consensus sequence was shown to be LITNTIAGV.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>12B5 1-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>GKLGLITNTIAGVAGLI</LinearSequence>
                                        <StartingPosition>477</StartingPosition>
                                        <EndingPosition>493</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>AAG40168.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <BCellId>2367949</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AdoptiveTransfer>
                            <RecipientOrganism>
                                <OrganismId>10000000</OrganismId>
                            </RecipientOrganism>
                            <TransferredAntibodyMolecule>
                                <TransferredAntibodyMoleculeSourceMaterial>Purified Immunoglobulin</TransferredAntibodyMoleculeSourceMaterial>
                                <TransferredAntibodyMoleculeImmunoglobulinDomain>Entire Antibody</TransferredAntibodyMoleculeImmunoglobulinDomain>
                                <TransferredAntibodyMoleculePurificationStatus>Monoclonal</TransferredAntibodyMoleculePurificationStatus>
                                <TransferredAntibodyMoleculeName>12B5 1-1</TransferredAntibodyMoleculeName>
                                <TransferredAntibodyHeavyChainType>IgG1</TransferredAntibodyHeavyChainType>
                            </TransferredAntibodyMolecule>
                            <AdoptiveTransferComments>Recipient mice received i.p. injections of 100, 50 or 25ug of the mAb 1 day before or 1 and 2 days following live challenge with 300 times the lethal does.</AdoptiveTransferComments>
                        </AdoptiveTransfer>
                        <AssayInformation>
                            <AssayTypeId>602</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <NumberOfSubjectsTested>10</NumberOfSubjectsTested>
                            <NumberOfSubjectsResponded>6</NumberOfSubjectsResponded>
                            <ResponseFrequency>60</ResponseFrequency>
                            <AssayComments>The epitope-specific mAb was shown to protect BALB/c and C57BL/6 mice from lethal challenge delivered prophylactically or therapeutically.</AssayComments>
                        </AssayInformation>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <BCellId>2367946</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>34</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb recognized Ebola virus - Mayinga, Zaire, 1976, but not Ebolavirus Sudan or Ivory Coast virus by ELISA.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>12B5 1-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Non-Native/Unknown</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
                <Assays>
                    <BCell>
                        <LocationOfData>Text page 1665</LocationOfData>
                        <BCellId>2367945</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>AAG40168.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>186538</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <RecombinantOrganism>
                                        <SubType>Recombinant Organism</SubType>
                                        <RecombinantOrganismId>11036</RecombinantOrganismId>
                                    </RecombinantOrganism>
                                </ImmunogenContainingObject>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>3 doses of 2X10&lt;sup&gt;6&lt;/sup&gt; FFU of VEE-GP at 1-month intervals</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were immunized with Venezuelan equine encephalitis virus (VEE) replicons encoding the GP protein of Ebola virus - Mayinga, Zaire, 1976. Spleens were removed 3 days after the final injection of 1X10&lt;sup&gt;7&lt;/sup&gt; FFU 21 days post boost and fused to P3X63Ag8.653 myeloma cells to produce hybridomas.</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>316</AssayTypeId>
                            <QualitativeMeasurement>Positive-Low</QualitativeMeasurement>
                            <AssayComments>The epitope-specific mAb was tested for its ability to inhibit plaque formation. This mAb did not reduce the number of plaques but did reduce their size.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Entire Antibody</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>12B5 1-1</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Organism</EpitopeRelation>
                                <Object>
                                    <Organism>
                                        <SubType>Organism</SubType>
                                        <SourceOrganismId>186538</SourceOrganismId>
                                    </Organism>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

